title: Redox-active and redox-silent compounds: synergistic therapeutics in cancer.
abstract: Tumours exhibit higher basal levels of reactive oxygen species (ROS) and altered redox environment compared to normal cells. Excessive level of ROS can be toxic to these cells, thus they become more vulnerable to damage by further ROS insults induced by pharmacological agents. However, the upregulation of antioxidant capacity in adaptation to intrinsic oxidative stress in cancer cells can confer drug resistance. Therefore, abrogation of such drug-resistant mechanisms by redox modulation could have significant therapeutic implications. Many redox-modulating agents have been developed. The redox-active system epitomised by ascorbate-driven quinone redox cycling, and the group of redox-silent vitamin E analogues represented by α-tocopheryl succinate have been shown to induce selective cancer cell death in different types of cancer. These compounds synergistically act by destabilising organelles like mitochondria, unleashing their apoptogenic potential, which results in efficient death of malignant cells and suppression of tumour growth. Consistent with this notion, clinical trials that aim to examine the therapeutic performance of novel redox-modulating drugs in cancer patients are currently under way.
authors.forename: M
authors.initials: M
authors.lastname: Tomasetti
authors.forename: L
authors.initials: L
authors.lastname: Santarelli
authors.forename: R
authors.initials: R
authors.lastname: Alleva
authors.forename: Lan-Feng
authors.initials: LF
authors.lastname: Dong
authors.affiliation: Griffith University, Southport, Qld 4222, Australia. jneuzil@img.cas.cz.
authors.forename: J
authors.initials: J
authors.lastname: Neuzil
mesh_terms: D017209:Apoptosis; D004357:Drug Synergism; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D010084:Oxidation-Reduction; D017382:Reactive Oxygen Species / Q000378:metabolism*
chemical_list: D017382:Reactive Oxygen Species